Community-Acquired Fungemia Due to a MultipleAzole-Resistant Strain of Candida tropicalis
Candida tropicalis is one of the more common causes of candidemia [1] . Recent reports describing clinical and in vitro resistance of Candida species associated with azole therapy have been of concern [2] [3] [4] . Azole-resistant Candida isolates have been identified, particularly in patients with advanced HIV disease. Resistance to fluconazole is infrequently described with regard to immunocompetent individuals [5] . Despite the increase in frequency of isolation, persistent candidemia due to azole-resistant C. tropicalis has not been previously reported. We report a patient from the community with C. tropicalis fungemia who remained candidemic despite high-dose fluconazole therapy.
A 46-year-old man with diabetes mellitus was admitted after being found unresponsive. His history included use of alcohol, injection drugs, and cigarettes. On admission he was unresponsive, with a blood pressure of 70 mm Hg over palpable, a pulse rate of 50/min, an oral temperature of 37.3ЊC, and a respiratory rate of 30 breaths/min. The remainder of his physical examination yielded nothing remarkable.
Laboratory values on admission included the following: serum glucose, 1215 mg/dL; bicarbonate, 4.1 mmol; and arterial pH, 6.99. After treatment with iv hydration and an insulin drip, he became more alert. Within 24 h his blood pressure normalized and his acidosis resolved. One day after admission a blood culture was reported positive for yeast, and fluconazole therapy at a dose of 400 mg/d was initiated. On day 3 the yeast was identified as C. tropicalis. In addition, a urine culture from the day of admission demonstrated the presence of C. tropicalis (1100,000 cfu/mL). Blood cultures performed on days 4, 8, 11, and 13 remained positive for C. tropicalis.
On day 13 the antifungal regimen was changed to administration of amphotericin B lipid complex at a dosage of 300 mg/d iv. An extensive evaluation was performed, and none of the studies demonstrated evidence of disseminated candidiasis. On day 28 the amphotericin was withdrawn and substituted Reprints with oral itraconazole (200 mg once daily for an additional 2 weeks). The patient recovered with no further medical problems and was discharged to home.
The identity of the C. tropicalis was established by means of the Yeast API 20C method (Analytab Products, Plainview, NY). In vitro susceptibilities were determined with use of the methodology of the National Committee for Clinical Laboratory Standards [6] . Strain delineation of the C. tropicalis isolates was established by electrophoretic karyotyping, which was performed according to the published method for contour-clamped homogeneous electric fields electrophoresis (CHEF) [7] . The results of in vitro susceptibility analysis of the isolates were identical and demonstrated in vitro cross-resistance (table 1) . Karyotyping revealed that the 5 C. tropicalis isolates were of the same strain. The ATCC isolate, however, was of a different strain type.
To our knowledge, azole-resistant C. tropicalis has not been previously reported as a cause of community-acquired candidemia. There is, however, 1 report of a patient with leukemia who developed fungemia with C. tropicalis while receiving fluconazole. Afterward, the isolate was found to be resistant to fluconazole [8] . Reports of studies that have evaluated the resistance of bloodstream isolates of C. tropicalis to fluconazole either focus on nosocomial infections or do not describe the origin of the isolates.
There are conflicting reports in the literature regarding the prevalence of resistance to C. tropicalis. A large multinational observational study that included the United States, Canada, and South America revealed that 99.4%-100% of the C. tropicalis isolates were susceptible to fluconazole [9] .
One possible explanation for resistance is that a susceptible strain might mutate and become resistant during therapy [10] . The patient described in this report presented to the hospital from the community with infection due to a strain of C. tro-picalis that was resistant to fluconazole, itraconazole, and clotrimazole. Because he had a history of injection drug use, it is possible that he may have been colonized by this strain of Candida for some time and acquired the fungemia from injecting. Although he was not HIV-positive, he may have shared needles or been exposed to someone who was HIV-positive and thus may have become colonized with the resistant C. tropicalis strain.
In addition, there are several recent reports describing antifungal cross-resistance among azoles. The majority of the Candida species isolates that have cross-resistance have been recovered from patients with advanced AIDS, low CD4 ϩ cell counts, a history of long-term antifungal use, and clinically refractory oropharyngeal and/or esophageal candidiasis [3, 4] .
This case is unusual for a variety of reasons. First, community-acquired C. tropicalis fungemia is an extremely uncommon infection, especially when the patient has no underlying risk factors associated with fungal infections. Second, it is uncommon to have fungemia with a non-albicans Candida species that is known to be azole-susceptible and demonstrates fluconazole resistance and high-level resistance to itraconazole and clotrimazole.
This observation once again raises questions regarding the incidence, acquisition, and mechanisms of resistance in fungal species causing infection in a patient population with few risk factors. In addition, it is essential to develop molecular techniques that may be used to identify organisms that may be resistant to the antifungals currently in use. in high percentages of primary effusion lymphomas, cases of multicentric Castleman's disease, and bone marrow dendritic cells of patients with myeloma. There is controversy about whether HHV-8 is ubiquitous and how the virus is transmitted in the healthy population. Reports on the frequency of virus shedding in the genital tract are being disputed, and the role of heterosexual transmission is also uncertain.
We have examined the presence of HHV-8 DNA in cervical scrapes from 404 consecutive Chinese women referred to a colposcopy clinic because of abnormal Papanicolaou smears. These patients were aged 16-88 years (mean, 40.6 years; SD, 11.7). None were commercial sex workers, 25% reported regular use of barrier contraception, 16% reported having 11 sexual partner, and 2% recalled having had sexually transmitted disease(s). None of the women were pregnant or had a history of cervical premalignant/malignant disease.
Colposcopy was performed for all the patients, and biopsies
